tiprankstipranks
Candel Therapeutics Unveils Breakthrough Immunotherapy Candidate
Company Announcements

Candel Therapeutics Unveils Breakthrough Immunotherapy Candidate

Pick the best stocks and maximize your portfolio:

Candel Therapeutics (CADL) has issued an update.

Candel Therapeutics, Inc. is set to unveil a pioneering immunotherapy candidate at the American Association for Cancer Research Annual Meeting on April 9, 2024. This second candidate, emerging from their enLIGHTENTM Discovery Platform, is designed to induce tertiary lymphoid structures and enhance anti-tumor immunity in solid tumors. Utilizing advanced analytics and in silico predictions, the therapy has shown promising results in mouse models, both alone and when combined with existing anti-PD-1 antibody treatments.

For detailed information about CADL stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyCandel Therapeutics Inc call volume above normal and directionally bullish
TheFlyCandel Therapeutics price target raised to $19 from $11 at H.C. Wainwright
TheFlyCandel Therapeutics Inc call volume above normal and directionally bullish
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App